Telix Pharmaceuticals’ (TLX) Outperform Rating Reiterated at Wedbush

Telix Pharmaceuticals (NASDAQ:TLX – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued on Wednesday, Benzinga reports. They currently have a $22.00 target price on the stock. Wedbush‘s price target would suggest a potential upside of 140.31% from the stock’s previous close.

Several other analysts have also issued reports on the stock. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, September 21st. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Friday, September 25th. Finally, Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $20.50.

Check Out Our Latest Stock Analysis on TLX

Telix Pharmaceuticals Stock Down 4.0%

NASDAQ TLX traded down $0.39 during trading hours on Wednesday, hitting $9.16. 258,036 shares of the company’s stock traded hands, compared to its average volume of 239,038. The business’s fifty day moving average price is $11.39 and its two-hundred day moving average price is $10.79. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $13.11.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals during the second quarter valued at $1,731,000. Private Advisor Group LLC increased its position in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after acquiring an additional 128,070 shares during the last quarter. XY Capital Ltd increased its position in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after acquiring an additional 58,739 shares during the last quarter. WoodTrust Financial Corp bought a new position in shares of Telix Pharmaceuticals in the third quarter worth about $186,000. Finally, Bank of America Corp DE grew its holdings in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares during the last quarter.

Telix Pharmaceuticals Company Profile

(Get Free Report)

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.

See Also

Analyst Recommendations for Telix Pharmaceuticals (NASDAQ:TLX)

Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.